Kura Oncology (KURA) CCO sells 10,000 shares in planned trade
Kura Oncology's Chief Commercial Officer, Brian T. Powl, sold 10,000 shares of common stock at $11.00 per share in an open-market transaction. This sale, totaling $110,000, was conducted under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025. Following the transaction, Powl directly holds 173,614 shares of Kura Oncology.
Kura Oncology’s SWOT analysis: biotech stock faces launch test
Kura Oncology (NASDAQ:KURA) is at a critical stage following the regulatory approval and initial commercial launch of its leukemia treatment, Komzifti. Despite lower-than-expected initial sales, analysts remain confident in the drug's long-term potential, especially with ongoing clinical trials expanding into larger market opportunities for first-line AML treatment. The company's financial health, characterized by more cash than debt, supports its transition from a clinical-stage to a commercial biotech, but continued losses are projected as it invests in launch infrastructure and further clinical development.
Kura Oncology’s SWOT analysis: biotech stock faces launch test
Kura Oncology (NASDAQ:KURA) is facing scrutiny over the commercial launch of its leukemia treatment, Komzifti, following lower-than-expected initial sales. Despite these challenges, the company's stock has seen a 78% return over the past year, and analysts remain confident in its long-term potential, especially given its clinical pipeline expansion into first-line AML treatments. The company's financial profile indicates a transition from clinical to commercial operations, with significant investment in both product launch and ongoing pivotal studies.
KURA (NASDAQ: KURA) files Form 144 reporting proposed sale of 10,000 RSUs
Kura Oncology, Inc. (NASDAQ: KURA) has filed a Form 144, indicating a proposed sale of 10,000 Restricted Stock Units (RSUs) with an aggregate value of $103,400.00. The filing also disclosed a prior 10b5-1 sale of 339 shares by Brian Powl on May 19, 2026, fetching $3,122.19. This Form 144 serves as a regulatory notice of an intended insider sale and not a confirmation of the transaction's completion.
Insider Sell: Brian Powl Sells Shares of Kura Oncology Inc (KURA)
Brian Powl, Chief Commercial Officer at Kura Oncology Inc, sold 339 shares of the company on May 19, 2026, reducing his total holdings to 183,614 shares. This transaction is part of a trend for Kura Oncology, which has seen 2 insider buys and 22 insider sells over the past year. Shares were trading at $9.21 each, giving the company a market capitalization of $917.931 million.
Kathleen Ford Sells 2,257 Shares of Kura Oncology Inc (KURA)
Kathleen Ford, COO of Kura Oncology Inc, sold 2,257 shares of the company on May 19, 2026, and now holds 153,560 shares. This transaction is part of a pattern where she has sold 17,864 shares over the past year with no purchases, contributing to a total of 2 insider buys and 22 insider sells for Kura Oncology Inc in the same period. On the day of the sale, Kura Oncology shares traded at $9.08, giving the company a market capitalization of $917.931 million.
Kura Oncology COO Kathleen Ford sells $20,482 in stock
Kura Oncology's COO, Kathleen Ford, sold 2,257 shares of the company's stock for $20,482 on May 19, 2026, a transaction executed under a Rule 10b5-1 trading plan. This sale occurred after a significant stock surge (62% annually, 9% weekly) and leaves Ford with 153,560 shares. Despite the stock's performance, InvestingPro analysis suggests it might be overvalued, and the company recently missed revenue forecasts while meeting EPS expectations in Q1 2026.
[Form 4] Kura Oncology, Inc. Insider Trading Activity
Kura Oncology, Inc.'s Chief Legal Officer, Teresa Brophy Bair, sold 2,256 shares of common stock at a weighted average price of $9.3795 per share through an open-market transaction. This sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on September 4, 2025. The shares sold were originally acquired via the company’s Employee Stock Purchase Plan on May 17, 2026, and following the transaction, Bair directly holds 226,931 shares of Kura Oncology common stock.
Kura Oncology (KURA) COO sells 2,257 shares under pre-set trading plan
Kura Oncology's Chief Operating Officer, Kathleen Ford, sold 2,257 shares of common stock on May 19, 2026, for approximately $20,500 under a pre-arranged 10b5-1 trading plan. The shares were acquired two days prior through the company's Employee Stock Purchase Plan. Following the transaction, Ford directly holds 153,560 shares of Kura Oncology common stock.
[144] Kura Oncology, Inc. SEC Filing
This article reports on Kura Oncology, Inc.'s SEC Form 144 filing from May 19, 2026. The filing indicates a proposed sale of 2,257 shares of common stock, valued at $20,764.40, acquired through an Employee Stock Purchase Plan. The transaction is marked as having a neutral impact and sentiment.
Kura Oncology to Present at TD Cowen 7th Annual Oncology Innovation Summit
Kura Oncology, Inc. announced its participation in the TD Cowen 7th Annual Oncology Innovation Summit, where its management will engage in a virtual fireside chat on May 26, 2026, at 1:30 p.m. ET. The company, a biopharmaceutical firm focused on precision medicines for cancer treatment, will make a webcast of the event available on its Investors section. Kura Oncology is known for developing and commercializing KOMZIFTI™ (ziftomenib), an FDA-approved menin inhibitor for acute myeloid leukemia.
Kura Oncology to Present at TD Cowen 7th Annual Oncology Innovation Summit
Kura Oncology, Inc. announced its participation in the TD Cowen 7th Annual Oncology Innovation Summit via a virtual fireside chat scheduled for May 26, 2026, at 1:30 p.m. ET. The event will be accessible live and as an archived replay on the Investors section of the company's website. Kura Oncology is a biopharmaceutical company focused on precision medicines for cancer, and recently commercialized KOMZIFTI™ (ziftomenib) for AML treatment.
[144] Kura Oncology, Inc. SEC Filing
Kura Oncology, Inc. filed a Form 144 with the SEC on May 18, 2026, indicating a proposed sale of 2256 shares of common stock with an aggregate market value of $20,800.32. The securities were acquired on May 17, 2026, through an Employee Stock Purchase Plan. The filing notes a neutral impact and sentiment regarding this transaction for the company.
Kura Oncology’s SWOT analysis: stock faces launch challenges despite FDA approval
Kura Oncology faces critical challenges in the commercial launch of its leukemia treatment, Komzifti, despite FDA approval in November 2025. Initial sales figures have fallen short of analyst expectations, raising questions about market adoption, although the company holds a strong liquid position with more cash than debt. The company's future growth hinges on successful expansion into first-line AML treatment, with ongoing pivotal studies presenting a significant upside potential despite projected losses in the short term.
Kura Oncology’s SWOT analysis: biotech stock faces launch challenges
Kura Oncology (NASDAQ:KURA) is at a pivotal stage, facing challenges with the commercial launch of its acute myeloid leukemia treatment, Komzifti (ziftomenib), despite FDA approval. While initial sales have been modest, the company is expanding ziftomenib's potential through clinical development for first-line AML treatment, offering a significantly larger market opportunity. The article conducts a SWOT analysis, highlighting the FDA approval as a strength and initial weak sales as a weakness, while ongoing clinical trials for broader indications present a major opportunity for future growth.
Kura Oncology’s SWOT analysis: biotech stock faces launch test
Kura Oncology (NASDAQ:KURA) is at a pivotal point, transitioning from clinical trials to commercialization following FDA approval in November 2025 for Komzifti (ziftomenib), a treatment for relapsed or refractory NPM1-mutated acute myeloid leukemia. Despite a 53% stock gain over the past year, initial commercial sales have been below expectations, raising questions about market adoption. The company is also pursuing broader market opportunities by evaluating ziftomenib in first-line AML treatment, which represents a significantly larger patient population and potential for future growth.
Earnings call transcript: Kura Oncology Q1 2026 revenue miss overshadows stable EPS
Kura Oncology reported its Q1 2026 earnings, meeting EPS expectations at -0.83 but missing revenue forecasts significantly with $18.27 million against an anticipated $25.4 million. Despite a post-earnings stock decline of 5.34%, the company's new product, KOMZIFTI, achieved a 40% market share in new patient starts during its first full quarter, generating $5.8 million in revenue. Kura anticipates collaboration payments and its cash position will fund its AML program through 2028, with upcoming data readouts expected to further strengthen its market position and product pipeline.
UBS Group AG Acquires 574,455 Shares of Kura Oncology, Inc. $KURA
UBS Group AG significantly increased its stake in Kura Oncology, Inc. (NASDAQ:KURA) by 118.3% in the fourth quarter, purchasing an additional 574,455 shares. This acquisition brings their total holdings to 1,060,025 shares, valued at approximately $11.0 million. Despite the stock seeing a 5.3% decline to $9.22, the company reported better-than-expected EPS for the quarter, though revenue fell short of estimates. Analyst sentiment generally remains a "Moderate Buy," with positive news around the early commercial launch of KOMZIFTI contributing to a constructive outlook, even as some analysts adjusted earnings estimates down due to ongoing losses.
Q2 EPS Estimates for Kura Oncology Lowered by HC Wainwright
HC Wainwright has lowered its Q2 2026 EPS estimate for Kura Oncology to -$0.89 from -$0.80, and also reduced forecasts for subsequent periods through FY2029, signaling a more cautious profit outlook for the biotech company. Despite the downward revision, Kura Oncology's recent quarterly results surpassed EPS expectations, reporting -$0.83 against a -$0.88 consensus, though revenue fell short. Analyst sentiment remains a "Moderate Buy" with a consensus price target of $26.38, reflecting mixed but generally constructive views.
Armistice Capital (KURA) holds 3.74M shares, 4.23% stake via Master Fund
Armistice Capital, LLC and Steven Boyd have filed Amendment No. 5 to a Schedule 13G/A, reporting shared beneficial ownership of 3,736,000 shares (4.23%) of Kura Oncology common stock as of March 31, 2026. This ownership is held by Armistice Capital Master Fund Ltd., with Armistice Capital acting as the investment manager exercising voting and investment power. The filing clarifies that the Master Fund disclaims beneficial ownership due to its Investment Management Agreement with Armistice Capital.
Analysts Have Lowered Expectations For Kura Oncology, Inc. (NASDAQ:KURA) After Its Latest Results
Kura Oncology, Inc. recently released its quarterly results, showing a 30% revenue miss, though losses per share were in line with forecasts. Analysts have since lowered revenue expectations for 2026 to US$97.6m from US$111.4m, while maintaining loss per share estimates at US$3.51. Despite the revenue downgrade, the consensus price target remained unchanged, suggesting the business is performing largely as expected, with projected revenue growth still outpacing the wider industry.
Kura Oncology stock (US50126D1028): Q1 earnings beat and analyst buys
Kura Oncology Inc. reported a Q1 2026 earnings beat with an EPS of -$0.83, exceeding estimates, and generated $5.8 million in net product revenue. Following this, major Wall Street banks reiterated buy ratings for the stock, with price targets ranging from $28 to $40. The company's focus on precision oncology with pipeline assets like ziftomenib and darlifarnib positions it strongly within the growing biotech sector.
Kura Oncology, Inc. (NASDAQ:KURA) Q1 2026 Earnings Call Transcript
Kura Oncology, Inc. reported strong Q1 2026 results, with Comzifty sales exceeding expectations at $5.8 million. The company is seeing broad market uptake and differentiation for Comzifty in the relapsed/refractory NPM1 mutant AML market, alongside significant progress in its Phase 3 programs and a robust pipeline for future expansion. Kura Oncology anticipates a steady flow of clinical data over the next 12-24 months, reinforcing its leadership in the menin inhibitor class and aiming to establish ziftomenib as a backbone therapy in AML.
Earnings Call Summary | Kura Oncology(KURA.US) Q1 2026 Earnings Conference
This document is an earnings call summary for Kura Oncology's Q1 2026 earnings conference. It provides an overview of the company's financial performance and key business updates for the first quarter of 2026.
Earnings Flash (KURA) Kura Oncology, Inc. Reports Q1 Revenue $18.3M, vs. FactSet Est of $26.0M
Kura Oncology, Inc. (KURA) reported its Q1 revenue, which totaled $18.3 million, falling short of FactSet's estimated $26.0 million. The oncology-focused biopharmaceutical company is currently trading at $9.680 USD with a change of +4.20% year-to-date. Recent news highlights ongoing clinical trials for its product candidates KOMZIFTI and Darlifarnib.
Kura Oncology Reports First Quarter 2026 Financial Results
Kura Oncology reported strong first-quarter 2026 financial results, with KOMZIFTI™ (ziftomenib) generating $5.8 million in net product revenue. The company highlighted robust early launch dynamics, including high patient uptake and broad payer coverage for KOMZIFTI, and anticipates multiple 2026 data readouts to further establish ziftomenib as a key treatment across Acute Myeloid Leukemia (AML). Kura Oncology projects its current cash and anticipated collaboration payments will fund the ziftomenib AML program through initial Phase 3 trial results in 2028.
Kura Oncology: Q1 Earnings Snapshot
Kura Oncology Inc. (KURA) reported a first-quarter loss of $73.3 million, or 83 cents per share, which surpassed Wall Street expectations. The biopharmaceutical company also recorded revenue of $18.3 million, exceeding analysts' forecasts. These results indicate better-than-expected financial performance for the quarter.
Kura Oncology: Q1 Earnings Snapshot
Kura Oncology Inc. reported a first-quarter loss of $73.3 million, or 83 cents per share, surpassing Wall Street expectations for a loss of 88 cents per share. The biopharmaceutical company also exceeded revenue forecasts, posting $18.3 million against an expected $15.1 million. This financial update was generated using data from Zacks Investment Research.
Kura Oncology Q1 2026 earnings preview
This article is a placeholder for a Q1 2026 earnings preview for Kura Oncology. No content was provided beyond the title.
Kura Oncology Inc expected to post a loss of 63 cents a share - Earnings Preview
Kura Oncology Inc is anticipated to report a loss of 63 cents per share, according to this earnings preview. The article, which is a brief Refinitiv report, solely focuses on this forecast for the company's upcoming financial results.
Kura Oncology to Participate in Bank of America Securities Healthcare Conference
Kura Oncology, Inc. announced its participation in the Bank of America Securities 2026 Healthcare Conference, where management is scheduled to hold a fireside chat on May 13, 2026. The biopharmaceutical company focuses on precision medicines for cancer treatment, with an FDA-approved drug, KOMZIFTI™, for a specific type of acute myeloid leukemia. A webcast of the event will be available on the company's investor relations website.
Kura Oncology to Participate in Bank of America Securities Healthcare Conference
Kura Oncology, Inc. announced its participation in the Bank of America Securities 2026 Healthcare Conference. Kura management is scheduled to hold a fireside chat on May 13, 2026, which will be accessible via webcast on the company's investor relations website. The company focuses on developing precision medicines for cancer treatment, including its FDA-approved drug KOMZIFTI™ (ziftomenib).
Kura Oncology to Report First Quarter 2026 Financial Results
Kura Oncology, Inc. will report its first quarter 2026 financial results after the close of U.S. financial markets on Tuesday, May 12, 2026. Management will host a webcast and conference call to discuss the results and provide a corporate update. The company is focused on precision medicines for cancer treatment, developing and commercializing drugs like KOMZIFTI™ for acute myeloid leukemia.
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology announced inducement grants of nonstatutory stock options to five new employees, totaling 133,750 shares of common stock. These grants were approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4) to incentivize employment. The stock options have an exercise price of $8.77 per share and will vest over four years.
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology, Inc. announced inducement awards granted on May 1, 2026, consisting of nonstatutory stock options to purchase 133,750 shares of common stock for five new employees. These awards, approved by the Compensation Committee, are an inducement for employment in accordance with Nasdaq Listing Rule 5635(c)(4), with an exercise price of $8.77 per share and a four-year vesting schedule. The grants align with the company's commitment to precision medicines for cancer treatment.
Five new Kura hires get stock options for 133,750 shares
Kura Oncology announced it granted inducement nonstatutory stock options to five new employees to purchase 133,750 shares under its 2023 Inducement Option Plan. The options have an exercise price of $8.77 per share, matching the closing price on May 1, 2026, and will vest over four years. This grant is made in accordance with Nasdaq Listing Rule 5635(c)(4).
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology announced the grant of inducement awards consisting of nonstatutory stock options to five new employees. These awards, totaling 133,750 shares of common stock, were approved by the Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $8.77 per share and will vest over four years, subject to continued employment.
Vanguard reports 5.01% stake in Kura Oncology (NASDAQ: KURA)
Vanguard Capital Management has reported a 5.01% beneficial ownership stake in Kura Oncology (NASDAQ: KURA), totaling 4,428,812 shares as of March 31, 2026. The Schedule 13G filing indicates Vanguard has sole dispositive power over all 4,428,812 shares and sole voting power for 643,127 shares. The shares are held by Vanguard funds and affiliates, with no single person's interest exceeding 5%.
Kura Oncology (KURA) Projected to Post Quarterly Earnings on Thursday
Kura Oncology (KURA) is set to release its Q1 2026 earnings before market open on Thursday, May 7th, with analysts forecasting an EPS of ($0.8099) and revenue of $25.77 million. The company missed prior-quarter expectations and has negative net margin and ROE, with analysts projecting negative EPS for the current and next fiscal years. Despite this, Wall Street generally holds a "Moderate Buy" rating with a target price of $26.38, and several large institutions have recently increased their holdings.
Kura Oncology (NasdaqGS:KURA) Stock Forecast & Analyst Predictions
Kura Oncology is projected to experience substantial growth in earnings and revenue, with analysts forecasting a 48.4% annual increase in earnings and 45.6% in revenue. Despite this, the company is expected to remain unprofitable for the next three years. Recent analyst commentary highlights both supportive and cautious views, largely revolving around the launch feedback and long-term potential of Kura Oncology's drug Komzifti, leading to slight adjustments in price targets.
Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML
Kyowa Kirin Co., Ltd. and Kura Oncology, Inc. have initiated a Japanese Phase 2 registrational clinical trial for ziftomenib, an oral menin inhibitor, aimed at treating relapsed or refractory (R/R) NPM1-mutated (NPM1-m) acute myeloid leukemia (AML). This trial, following ziftomenib's U.S. FDA approval in November 2025, marks a significant step towards providing a new treatment option for AML patients in Japan. The companies are working in collaboration on the development and commercialization of menin inhibitors globally.
Kyowa Kirin Co., Ltd. And Kura Oncology, Inc. Advance Ziftomenib With Japan Phase 2 Trial In NPM1 Mutated AML
Kyowa Kirin Co., Ltd. and Kura Oncology, Inc. have initiated a Phase 2 registrational clinical trial in Japan for ziftomenib, an oral menin inhibitor aimed at treating relapsed or refractory NPM1-mutated acute myeloid leukemia (AML). This step is crucial for potential regulatory approval in Japan, following its FDA approval in November 2025 for similar patient populations in the U.S. The trial seeks to confirm the drug's efficacy and safety, addressing a significant unmet medical need for AML patients.
Kyowa Kirin Co., Ltd. And Kura Oncology, Inc. Advance Ziftomenib With Japan Phase 2 Trial In NPM1 Mutated AML
Kyowa Kirin Co., Ltd. and Kura Oncology, Inc. have advanced their collaboration on ziftomenib, an oral menin inhibitor, by dosing the first patient in a Japanese Phase 2 registrational clinical trial for relapsed or refractory NPM1-mutated acute myeloid leukemia (AML). This trial, a significant step toward potential regulatory approval in Japan, follows the FDA's approval of ziftomenib (KOMZIFTI™) in November 2025 for similar patient populations in the U.S. The companies aim to address unmet medical needs by bringing this new treatment option to patients in Japan, with plans for additional studies in combination therapies for front-line AML treatment.
Kura Oncology, Inc. (KURA) Discusses Updated Data on Darlifarnib and Cabozantinib Combination in Advanced Renal Cell Carcinoma - Slideshow (NASDAQ:KURA)
Kura Oncology, Inc. (KURA) held an event to discuss updated data on the darlifarnib and cabozantinib combination in advanced renal cell carcinoma. A slide deck related to this event was published by the company. The information was disseminated through SA Transcripts.
Kura Oncology, Inc. (KURA) Discusses Updated Data on Darlifarnib and Cabozantinib Combination in Advanced Renal Cell Carcinoma - Slideshow (NASDAQ:KURA) 2026-04-21
Kura Oncology, Inc. presented updated data on the combination of darlifarnib and cabozantinib for advanced renal cell carcinoma. The information was released in a slide deck in conjunction with an event. This article was prepared by the Seeking Alpha transcripts team.
Barclays Sticks to Their Buy Rating for Kura Oncology (KURA)
Barclays analyst Etzer Darout has maintained a Buy rating on Kura Oncology (KURA) with a price target of $28.00. The company recently reported a quarterly revenue of $17.34 million and a GAAP net loss of $81 million. Despite the analyst's positive outlook, corporate insider sentiment for KURA is negative, with an increase in insider selling reported over the past quarter.
H.C. Wainwright Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $40
H.C. Wainwright has reiterated its Buy rating for Kura Oncology (KURA.US) and maintained its target price at $40. This indicates the firm's continued positive outlook on the company's stock performance.
Kura Oncology (KURA) Moves 8.3% Higher: Will This Strength Last?
Kura Oncology (KURA) shares recently rallied 8.3% following promising preliminary data from its FIT-001 study, which is evaluating darlifarnib in combination with cabozantinib for clear cell renal cell carcinoma. Despite this positive news, the company is expected to post a quarterly loss, and earnings estimate revisions show a negative trend, leading to a Zacks Rank of #3 (Hold). Investors should monitor if the recent stock jump can be sustained.
Kura rises after early-stage trial data for kidney cancer therapy
The provided article content is empty. Therefore, a summary cannot be generated.
Kura Oncology, Inc. (NASDAQ:KURA) Given Average Recommendation of "Moderate Buy" by Brokerages
Kura Oncology, Inc. (NASDAQ:KURA) has received a "Moderate Buy" recommendation from thirteen brokerages, with an average 12-month price target of $26.38. Despite this, the company missed quarterly earnings and revenue expectations, reporting ($0.92) EPS against a consensus of (−$0.72) and revenue of $17.34 million against estimates of $34.71 million. Insiders have also recently sold shares, with 36,068 shares valued at $305,135 sold in the last quarter, reducing insider ownership to 6.40%.
